After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. The small-molecule drug is now allowed for patients 12 years of age and older ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results